Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | RXRB | P28702 | 6/20 | 0.36 |
| ▸ | RXRA | P19793 | 5/20 | 0.36 |
| ▸ | RXRG | P48443 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114278 | 1.00 | LMNA (0.40) | LMNAKDM4ENPC1SMN1; SMN2RAB9A | |
| SCHEMBL20490101 | 0.76 | HTR2B (0.38) | ALDH1A1RXRBRXRARXRGSIGMAR1 | |
| SCHEMBL5427637 | 0.75 | ALDH1A1 (0.41) | LMNANPC1SMN1; SMN2MAPTHDAC6 | |
| SCHEMBL30071655 | 0.75 | ALDH1A1 (0.41) | LMNANPC1SMN1; SMN2MAPTHDAC6 | |
| SCHEMBL3105338 | 0.75 | ALDH1A1 (0.43) | LMNAKDM4ENPC1SMN1; SMN2RAB9A | |
| SCHEMBL5427633 | 0.75 | ALDH1A1 (0.41) | LMNANPC1SMN1; SMN2MAPTHDAC6 | |
| SCHEMBL3105348 | 0.75 | ALDH1A1 (0.43) | LMNAKDM4ENPC1SMN1; SMN2RAB9A | |
| SCHEMBL5430618 | 0.75 | HTT (0.43) | LMNANPC1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL30071721 | 0.75 | HTT (0.43) | LMNANPC1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL5430622 | 0.75 | HTT (0.43) | LMNANPC1SMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | claimed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | claimed |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2016-12-29 | — | — | US | claimed |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2010-10-07 | — | — | US | claimed |
| CN-101827589-A | Hepatitis c antiviral compositions and methods | BIOTROM LTD | 2010-09-08 | — | — | CN | claimed |
| EP-2194976-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | Biotron Limited (AU) | 2010-06-16 | — | — | EP | claimed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | claimed |
| WO-2009018609-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTROM LIMITED (AU) | 2009-02-12 | — | — | WO | claimed |
| JP-2008543886-A | — | — | 2008-12-04 | — | — | JP | claimed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | claimed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | claimed |
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2020-12-10 | — | — | US | disclosed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | disclosed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | disclosed |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2017-12-21 | — | — | US | disclosed |
| EP-2194976-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | Biotron Limited (AU) | 2010-06-16 | — | — | EP | disclosed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | disclosed |
| WO-2009018609-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTROM LIMITED (AU) | 2009-02-12 | — | — | WO | disclosed |
| EP-1902017-A1 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006135978-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | LMNA 2837/4885KDM4E 3855/4885NPC1 560/4885 |
| US-10683263-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | LMNA 3096/4885KDM4E 2925/4885NPC1 333/4885 |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | LMNA 2837/4885KDM4E 3855/4885NPC1 560/4885 |
| US-20090099239-A1 | Antiviral Compounds and Methods | MAVS, ZC3HAV1, EIF2AK2 | LMNA 3096/4885KDM4E 2925/4885NPC1 333/4885 |
| US-20160376231-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | LMNA 3096/4885KDM4E 2925/4885NPC1 333/4885 |
| US-20200385340-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | LMNA 2837/4885KDM4E 3855/4885NPC1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.